Insmed, Inc. (INSM)
121.51
-0.31
(-0.25%)
USD |
NASDAQ |
Sep 01, 16:00
121.51
0.00 (0.00%)
After-Hours: 20:00
Insmed Research and Development Expense (Annual) : 771.09M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 771.09M |
| December 31, 2024 | 598.37M |
| December 31, 2023 | 571.01M |
| December 31, 2022 | 397.52M |
| December 31, 2021 | 272.74M |
| December 31, 2020 | 181.16M |
| December 31, 2019 | 131.71M |
| December 31, 2018 | 145.28M |
| December 31, 2017 | 109.75M |
| December 31, 2016 | 122.72M |
| December 31, 2015 | 74.28M |
| December 31, 2014 | 56.29M |
| December 31, 2013 | 44.28M |
| December 31, 2012 | 29.78M |
| Date | Value |
|---|---|
| December 31, 2011 | 27.92M |
| December 31, 2010 | 4.757M |
| December 31, 2009 | 9.207M |
| December 31, 2008 | 21.05M |
| December 31, 2007 | 18.94M |
| December 31, 2006 | 21.09M |
| December 31, 2005 | 8.938M |
| December 31, 2004 | 23.32M |
| December 31, 2003 | 7.14M |
| December 31, 2002 | 18.08M |
| December 31, 2001 | 35.51M |
| December 31, 2000 | 21.61M |
| December 31, 1999 | 7.376M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Biogen, Inc. | 1.481B |
| Gilead Sciences, Inc. | 5.688B |
| Agios Pharmaceuticals, Inc. | 334.36M |